Findings

What do systematic reviews say?

4 questions · 7 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 3 · 42.9%Moderate 1 · 14.3%High 2 · 28.6%

Tumour response · people with advanced gastric cancer

Irinotecan may leads to higher tumour response compared with non‐irinotecan‐containing regimens (low certainty).

4 findings from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
OR 1.72 [1.24, 2.4]
10 studies · 1266 participants
Low
Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
OR 1.53 [0.93, 2.5]
6 studies · 756 participants
Low
Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
OR 2.18 [1.25, 3.8]
3 studies · 345 participants
Low

Show 1 more finding

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
OR 1.87 [0.89, 3.91]
2 studies · 165 participants
Very low

Tumour response · people with metastatic CRC

Irinotecan + oxaliplatin probably leads to higher overall tumour response compared with irinotecan (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 2.98 [1.91, 4.64]
1 study · 627 participants
Moderate

Tumour response · people with metastatic CRC

Irinotecan‐based regimens leads to higher overall tumour response compared with irinotecan (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 2.87 [2.1, 3.93]
6 studies · 2577 participants
High

Tumour response · people with metastatic CRC

Irinotecan + targeted therapy leads to higher overall tumour response compared with irinotecan (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 3.38 [2.53, 4.52]
2 studies · 1758 participants
High